Needle-free Delivery of Polio Vaccine

Inactivated polio vaccine (IPV) delivered intradermally with Tropis® can save money, improve beneficiary experience, achieve higher efficacy, and increase vaccine coverage.


Increased Coverage

Improved Performance

Doing Our Part in the Next Step Towards Polio Eradication

The WHO recommends 2 doses of IPV to minimize vaccine-derived poliovirus (VDPV). With Tropis, you can save costs on routine immunization and campaigns while increasing immunization coverage.

Key Benefits of Polio Vaccine Delivered Intradermally, Needle-free

Comparable Protection

Two intradermal doses of IPV (fIPV) provide the same or improved protection as two IM IPV doses. WHO endorses fIPV as a means of extending stocks and saving costs.

Reduces Costs

Countries transitioning from Gavi support can save tens of millions of dollars by switching to ID IPV delivered needle-free. We can show you how!

Easy to Roll Out

Needle-free injection systems are easy to learn. After about 20 minutes, most users are highly proficient. Experienced users would prefer to use needle-free

Tropis is Playing a Part in Polio Eradication
Around the World

PharmaJet’s Needle-free Injection System was selected to deliver IPV in Pakistan and Somalia catch-up campaigns based on its proven cost-savings, ease of training, and improved coverage benefits.


  • 2021 campaign: 110,000 children immunized
  • 100% caregivers surveyed reported they would be more likely to bring their children for vaccination in a future needle-free campaign
  • 100% healthcare workers surveyed said that using needle-free injectors could increase vaccination rates


  • 2018/2019 campaigns: > 3m immunized
  • 97.6% vaccinators prefer jet injectors to needle and syringe
  • 99.6% of caretakers prefer jet injectors to needle and syringe
  • Mean coverage over previous IPV campaign improved 18.4%

Implementation Experience is the Key to Success

PharmaJet is happy to support you in developing a pilot study to assess the integration of Tropis ID into your routine and campaign immunization programs while measuring the direct benefits with regards to cost, user preference, and coverage.